MedTrace Logo

Breast Screening Atypia and Subsequent Development of Cancer in England

NCT05402436 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3238

Last updated 2025-01-16

No results posted yet for this study

Summary

During breast screening, atypical epithelial proliferations (atypia) can be detected. These are not cancer, but may mean that a woman is more likely to develop breast cancer in the future. This study explores how atypia develop into breast cancer in terms of number of women, time to cancer development, cancer type and severity, and whether this varies for different types of atypia. The results will be used to create new guidelines for how women with atypia should be followed up.

Conditions

Interventions

OTHER

A diagnosis of atypia as part of the English screening programme

An atypia diagnosis of either ADH (including AIDEP), LISN (both ALH and LCIS) or FEA

Sponsors & Collaborators

  • University Hospitals Coventry and Warwickshire NHS Trust

    collaborator OTHER

  • King's College London

    collaborator OTHER

  • The Leeds Teaching Hospitals NHS Trust

    collaborator OTHER

  • University of Warwick

    lead OTHER

Eligibility

Min Age
47 Years
Max Age
73 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-12-30
Completion
2023-12-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05402436 on ClinicalTrials.gov